ConditionICD-10: I25

Cardiovascular Disease

Cardiovascular disease (CVD) is the leading cause of death in the United States, accounting for ~700,000 deaths annually. It includes coronary artery disease (the most common form), heart failure, stroke, peripheral artery disease, and atrial fibrillation. Obesity and type 2 diabetes both dramatically increase CVD risk — and certain GLP-1 medications have demonstrated independent cardiovascular benefit beyond their weight-loss and glucose-lowering effects, leading to specific FDA-approved cardiovascular indications.

Key facts

•CVD causes ~700,000 US deaths per year — leading cause of death
•Wegovy FDA-approved (March 2024) to reduce risk of major cardiovascular events in adults with overweight/obesity + established CVD
•Ozempic + Trulicity FDA-approved for cardiovascular risk reduction in type 2 diabetes
•SELECT trial showed Wegovy reduced MACE (major adverse cardiovascular events) by 20% over ~3 years
•Cardiovascular benefit appears independent of weight loss — direct vascular effects + inflammation reduction
•Most US adults underestimate their personal CVD risk

Why GLP-1 medications

GLP-1 medications produce cardiovascular benefit through multiple overlapping mechanisms: weight loss reduces afterload and improves metabolic profile; glucose control reduces vascular damage in diabetic patients; direct vascular effects include reduced inflammation, improved endothelial function, and modest blood-pressure reduction. The SELECT trial (2023 NEJM) demonstrated Wegovy reduced major adverse cardiovascular events by 20% over 33 months in patients with overweight/obesity + established CVD — leading to FDA approval of a specific cardiovascular indication for Wegovy in March 2024. Similar trials drove earlier FDA cardiovascular indications для Ozempic, Trulicity, and Victoza in type 2 diabetes populations.

Common symptoms

Chest pain, pressure, or discomfort (especially with exertion)
Shortness of breath at rest or with mild activity
Palpitations или irregular heartbeat sensations
Swelling in legs, ankles, or feet (heart failure sign)
Sudden weakness or numbness on one side (stroke warning)
Sudden severe headache (stroke warning)
Pain in the calf when walking (peripheral artery disease)
Fatigue or reduced exercise tolerance

How cardiovascular disease is diagnosed

CVD diagnosis depends on the specific condition. Coronary artery disease typically diagnosed via combination of risk factor assessment (age, sex, blood pressure, lipids, diabetes status, smoking), exercise stress testing, coronary CT angiography, or invasive coronary catheterization. Heart failure diagnosis uses echocardiography, BNP/NT-proBNP labs, and clinical assessment. The American College of Cardiology/American Heart Association (ACC/AHA) risk calculator estimates 10-year CVD risk and guides preventive medication decisions including statins, ACE inhibitors, and now (для eligible patients) GLP-1 therapy.

Treatment options

Lifestyle (foundation)

Mediterranean or DASH diet, 150+ min/week moderate exercise, smoking cessation, weight management. Underpins all other treatment.

GLP-1 medications (newer cardiovascular indication)

Wegovy FDA-approved for CV risk reduction in adults with overweight/obesity + established CVD. Ozempic, Trulicity, Victoza approved for CV risk reduction in type 2 diabetes.

Statins (cholesterol)

Atorvastatin, rosuvastatin, others. Reduce LDL cholesterol and lower CV events by 25-35% in eligible patients.

Antihypertensives

ACE inhibitors, ARBs, calcium channel blockers, beta blockers. Target BP <130/80 in most adults with CVD.

Antiplatelets

Aspirin (low-dose), clopidogrel — prevent clot formation in established CVD.

SGLT2 inhibitors (newer class)

Empagliflozin, dapagliflozin — provide CV + kidney benefit in diabetic patients. Often combined с GLP-1.

Interventional / surgical

Coronary angioplasty + stent, coronary artery bypass grafting, valve replacement, implantable defibrillators per specific condition.

Lifestyle & self-care

Mediterranean or DASH eating pattern — strongest evidence for CV outcomes
150-300 min/week moderate-intensity exercise + 2 sessions strength training
Tobacco cessation — quitting smoking is the single highest-impact CV intervention
Limit alcohol (≤1 drink/day women, ≤2 men per US guidelines)
Manage stress — chronic stress contributes to hypertension and CV events
7-9 hours sleep per night — sleep deprivation increases CV risk
BP self-monitoring at home if hypertensive

When to see a doctor

Make an appointment if you have:

→Chest pain or pressure — особенно if exertional, radiating, or new
→Shortness of breath at rest or with mild activity
→Sudden severe headache, weakness, vision change, or speech change (call 911)
→Palpitations с lightheadedness
→Family history of early heart disease + age ≥40 (screening recommended)
→Diabetes, hypertension, or high cholesterol diagnosis (need comprehensive CV risk assessment)
→Considering GLP-1 therapy с history of CVD or multiple CV risk factors

Medications for Cardiovascular Disease

Zepbound

tirzepatide

From $349/mo

Mounjaro

tirzepatide

From $1023/mo

Wegovy

semaglutide

From $1349/mo

Ozempic

semaglutide

From $968/mo

Not sure which medication is right for you?

Take our 60-second quiz and get a personalized match.

Take the quiz

Sources

Educational content; not a substitute for professional medical advice. Always consult a licensed clinician.